Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

ClinicalTrials.gov ID: NCT05381948

Public ClinicalTrials.gov record NCT05381948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.

Study identification

NCT ID
NCT05381948
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Enrollment
161 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2022 (Actual)
Primary completion
Nov 29, 2023 (Actual)
Completion
Apr 24, 2024 (Actual)
Last update posted
Oct 15, 2025

2022 – 2024

United States locations

U.S. sites
67
U.S. states
25
U.S. cities
67
Facility City State ZIP Site status
EyePoint Investigative Site Phoenix Arizona 85053 —
EyePoint Investigative Site Springdale Arkansas 72762 —
EyePoint Investigative Site Beverly Hills California 90211 —
EyePoint Investigative Site Campbell California 95008 —
EyePoint Investigative Site Encino California 91436 —
EyePoint Investigative Site Fullerton California 92835 —
EyePoint Investigative Site Glendale California 91203 —
EyePoint Investigative Site Huntington Beach California 92647 —
EyePoint Investigative Site Irvine California 92697 —
EyePoint Investigative Site Pasadena California 91107 —
EyePoint Investigative Site Poway California 92064 —
EyePoint Investigative Site Redlands California 92373 —
EyePoint Investigative Site Sacramento California 95825 —
EyePoint Investigative Site Walnut Creek California 94598 —
EyePoint Investigative Site Lakewood Colorado 80228 —
EyePoint Investigative Site Clearwater Florida 33761 —
EyePoint Investigative Site Coral Springs Florida 33067 —
EyePoint Investigative Site Lakeland Florida 33805 —
EyePoint Investigative Site Melbourne Florida 32901 —
EyePoint Investigative Site Miami Florida 33143 —
EyePoint Investigative Site Pensacola Florida 32503 —
EyePoint Investigative Site Sarasota Florida 34239 —
EyePoint Investigative Site St. Petersburg Florida 33711 —
EyePoint Investigative Site Tampa Florida 33609 —
EyePoint Investigative Site Winter Haven Florida 33880 —
EyePoint Investigative Site Marietta Georgia 30060 —
EyePoint Investigative Site ‘Aiea Hawaii 96701 —
EyePoint Investigative Site Chicago Illinois 60616 —
EyePoint Investigative Site Lemont Illinois 60439 —
EyePoint Investigative Site Carmel Indiana 46290 —
EyePoint Investigative Site West Des Moines Iowa 50266 —
EyePoint Investigative Site Baltimore Maryland 21209 —
EyePoint Investigative Site Hagerstown Maryland 21740 —
EyePoint Investigative Site Owings Mills Maryland 21117 —
EyePoint Investigative Site Boston Massachusetts 02114 —
EyePoint Investigative Site Springfield Massachusetts 01107 —
EyePoint Investigative Site Grand Rapids Michigan 49446 —
EyePoint Investigative Site Saint Louis Michigan 55416 —
EyePoint Investigative Site St Louis Missouri 63128 —
EyePoint Investigative Site Reno Nevada 89502 —
EyePoint Investigative Site Teaneck New Jersey 07666 —
EyePoint Investigative Site Great Neck New York 11021 —
EyePoint Investigative Site Hauppauge New York 11788 —
EyePoint Investigative Site Liverpool New York 13088 —
EyePoint Investigative Site Shirley New York 11967 —
EyePoint Investigative Site Asheville North Carolina 28803 —
EyePoint Investigative Site Wake Forest North Carolina 27587 —
EyePoint Investigative Site Eugene Oregon 97401 —
EyePoint Investigative Site Portland Oregon 97239 —
EyePoint Investigative Site Springfield Oregon 97488 —
EyePoint Investigative Site Charleston South Carolina 29414 —
EyePoint Investigative Site West Columbia South Carolina 29169 —
EyePoint Investigative Site Germantown Tennessee 38138 —
EyePoint Investigative Site Nashville Tennessee 37203 —
EyePoint Investigative Site Abilene Texas 79606 —
EyePoint Investigative Sites Austin Texas 78750 —
EyePoint Investigative Site Dallas Texas 75231 —
EyePoint Investigative Sites Houston Texas 77025 —
EyePoint Investigative Site McAllen Texas 78503 —
EyePoint Investigative Site Plano Texas 75075 —
EyePoint Investigative Site San Antonio Texas 78240 —
EyePoint Investigative Site The Woodlands Texas 77384 —
EyePoint Investigative Site Salt Lake City Utah 84107 —
EyePoint Investigative Site Fairfax Virginia 22031 —
EyePoint Investigative Site Lynchburg Virginia 24502 —
EyePoint Investigative Site Warrenton Virginia 20186 —
EyePoint Investigative Site Silverdale Washington 98383 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05381948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2025 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05381948 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →